基底核心启动子突变比例对HBeAg血清学转换后肝纤维化进展的影响
该研究对160例初始HBeAg阳性慢性HBV感染者,在炎症期和HBeAg血清学转换后,通过焦磷酸测序定量HBV突变比例,并分析抗病毒药物、突变比例与肝脏硬度测量值(LSM)的关系。抑制肝细胞PD-L1可能是该突变引发肝脏炎症的机制之一。
要点
- HBeAg血清学转换年龄与炎症期A1762T/G1764A突变比例呈正相关。
- HBeAg血清学转换前接受干扰素、恩替卡韦或替诺福韦酯治疗者,转换后A1762T/G1764A突变比例较低。
核心结论
- HBeAg血清学转换后A1762T/G1764A突变比例与肝纤维化相关,该突变可能通过抑制肝细胞PD-L1引发肝脏炎症。
研究设计与样本
- 研究纳入160例初始HBeAg阳性慢性HBV感染者,在炎症期和HBeAg血清学转换后采集血清,用焦磷酸测序定量HBV突变比例,并分析抗病毒药物、突变比例与LSM的关系。
主要发现
- HBeAg血清学转换后,LSM>7 kPa者的A1762T/G1764A突变比例显著高于LSM≤7 kPa者。
- HBeAg血清学转换年龄与转换前炎症期A1762T/G1764A突变比例呈正相关。
- 转换前接受干扰素、恩替卡韦或替诺福韦酯治疗者,转换后A1762T/G1764A突变比例较低。
- A1762T/G1764A突变存在时,肝细胞中程序性死亡配体-1(PD-L1)的信使核糖核酸和蛋白水平下调。
临床怎么用
- 对HBeAg血清学转换后的慢性HBV感染者,可关注A1762T/G1764A突变比例,≥20%提示肝纤维化风险较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We investigated the relationships among the percentage of hepatitis B virus (HBV) mutations and liver fibrosis after hepatitis B e antigen (HBeAg) seroconversion. METHODS: We quantified the percentage of HBV mutants by pyrosequencing using serum samples obtained at inflammatory phase and after HBeAg seroconversion in 160 initially HBeAg-positive chronic HBV-infected patients. The relationships between antiviral agents, percentages of HBV mutations, and liver stiffness measurements (LSMs) were analyzed. RESULTS: We demonstrated that the percentages of A1762T/G1764A mutation are significantly higher in subjects with an LSM >7 kPa than in those with an LSM ≤7 kPa after HBeAg seroconversion. Hepatitis B e antigen seroconversion age is positively correlated with the percentages of A1762T/G1764A mutation at inflammatory phase before HBeAg seroconversion. Subjects who underwent interferon, entecavir, or tenofovir disoproxil fumarate therapy before HBeAg seroconversion possessed a lower percentage of A1762T/G1764A mutation after HBeAg seroconversion. The percentage of A1762T/G1764A ≥20% after HBeAg seroconversion was predictive of an LSM >7 kPa (hazard ratio = 6.37, P = .001). The presence of A1762T/G1764A led to downregulated messenger ribonucleic acid and protein levels of programmed-death ligand-1 (PD-L1) in hepatocytes. CONCLUSIONS: The percentage of A1762T/G1764A mutations after HBeAg seroconversion was associated with liver fibrosis. The A1762T/G1764A mutation may evoke hepatic inflammation by suppressing PD-L1 in hepatocytes.
引用
- Wu JF, Chang KC, Ni YH, et al. Impacts of the Percentage of Basal Core Promoter Mutation on the Progression of Liver Fibrosis After Hepatitis B e Antigen Seroconversion. J Infect Dis. 2021. PMID: 32860707. doi:10.1093/infdis/jiaa545
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。